Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial assessed the safety of human umbilical cord mesenchymal stem cell therapy
in 15 patients with diabetic nephropathy. Fifteen subjects received umbilical cord
mesenchymal stem cell therapy 3 times. Approximately 1 × 106/kg of human umbilical cord
mesenchymal stem cells were administered by peripheral intravenous infusion once a month
.Endpoints:Primary endpoint: Safety and adverse events (safety and tolerability of umbilical
cord mesenchymal stem cell therapy within 60 weeks).Secondary endpoint indicators:Efficacy
measures: eGFR, urinary albumin-to-creatinine ratio, and percentage changes of 24-h urinary
protein quantities from baseline to 60 weeks.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yan'an Affiliated Hospital of Kunming Medical University